Repurposing Drugs by In Silico Methods to Target BCR Kinase Domain in Chronic Myeloid Leukemia

BACKGROUND: Targeted therapy in the form of highly selective tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). However, mutations in the kinase domain contribute to drug resistance against TKIs which compromises the treatment response. Our aim is to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Natarajan, Aparna, Thangarajan, Rajkumar, Kesavan, Sabitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063026/
https://www.ncbi.nlm.nih.gov/pubmed/31759365
http://dx.doi.org/10.31557/APJCP.2019.20.11.3399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063026/
https://www.ncbi.nlm.nih.gov/pubmed/31759365
http://dx.doi.org/10.31557/APJCP.2019.20.11.3399

Ejemplares similares